Dr. Herbst is a Professor of Medicine and Pharmacology, Chief of the Medical Oncology and Associate Director for Translational Science at Yale School of Medicine and Yale Cancer Center (YCC). Prior to his appointment at Yale, Herbst was a professor of medicine, chief of the Section of Thoracic Medical Oncology, and the Barnhart Family Distinguished Professor in Targeted Therapies at MD Anderson Cancer Center. His primary mission is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to cancer patients.
Dr. Herbst’s laboratory work is focused on angiogenesis and dual EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways. This work has been translated from the preclinical to clinical setting in multiple phase II and III studies which he has led. He has led the Phase I development of several of the new generation of targeted agents for NSCLC, including gefitinib, erlotinib, and bevacizumab. He co-led the BATTLE-1 effort at M.D. Anderson Cancer Center and now leads the BATTLE-2 clinical program at Yale. He serves as a Co-Program Leader of the Developmental Therapeutics Program at YCC.
Dr. Herbst is a member of the National Cancer Policy Forum for which he has organized an IOM meeting focused on policy issues in personalized medicine. He is a member of the American Association of Cancer Research (AACR), where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology and the Institute of Medicine’s National Cancer Policy Forum. He is a fellow of the American College of Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for the International Association for the Study of Lung Cancer. He has authored more than 200 peer-reviewed papers and has current grant funding for his work from numerous sources including the National Cancer Institute, AACR and multiple charitable foundations.
After earning a B.S. and M.S. from Yale University summa cum laude, he received his medical degree from Cornell University Medical College and earned a Ph.D. in molecular cell biology from the Rockefeller University. Dr. Herbst completed his medical oncology fellowship at Dana Farber Cancer Institute and a medical hematology fellowship at Brigham and Women’s Hospital in Boston, where he additionally received a master’s degree from Harvard University in their clinical investigator training program.
Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians
Patient Care Organizations
Medical Oncology: Subset Medical Oncology Faculty
Medical Oncology AB of Internal Medicine (1997)
|Lung||A randomized phase II trial of combination versus single agent chemotherapy in high-risk elderly pat|
|Lung||Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)|
|Lung||PINNACLE: Phase 1b/2 Study of Anti-Notch Antibody Therapy with Cisplatin and Etoposide in SCLC|
|Lung, Melanoma, skin||Evaluating the Combination of MK-3475 and Sterotactic Body Radiotherapy in Patients With Metastatic|
|Unknown Sites||Novel Treatment to Enhance Smoking Cessation before Cancer Surgery|
|Lung||A Study of MPDL3280A in Combination With INCB024360 in Subjects With Previously Treated Stage IIIB o|
|Lung||Phase II Study of MEDI4736 in Locally Advanced or Metastatic NSCLC|
|Lung||Safety and Efficacy of Abraxane Maintenance post Abraxane + Carboplatin in squamous cell lung cancer|
|Lung||Phase I Study of DNIB0600A in NSCLC and Ovarian Cancer|
|Lung||Biomarker-Driven Master Protocol for Squamous Cell Lung Cancer|
|Melanoma, skin||PF-05082566 + MK-3475 IN ADVANCED SOLID TUMORS|
|Lung, Melanoma, skin||Phase 2 Study of MK-3475 in Patients with Melanoma or NSCLC with Untreated Brain Mets|
|Lung||Phase 1b study of MPDL3280A with erlotinib in advanced NSCLC|
|Colon, Kidney, Lung, Other Digestive Organ, Rectum, Stomach||Phase Ib Trial of MPDL3280A with Bev or with Bev + FOLFOX in Patients with Solid Tumors|
|Bladder, Breast - Female, Lung, Ovary, Pancreas, Stomach||Phase 1/2 Study of Nivolumab or Nivolumab with Ipilimumab for Advanced or Metastatic Solid Tumors|
|Lung||Phase Ib study of MEDI4736 with Tremelimumab in Advanced NSCLC|
|Lung||Lung Cancer Mutation Consortium Protocol|
|Lung||S1206 (8811): Ph I/II randomized Veliparib vs. placebo + Carboplatin & Paclitaxel for Stg III NSCLC|
|Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid||PCD4989g: Phase I, Open-label MPDL3280A in solid tumors|